Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Robert J. Mayer, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Faculty Vice President for Academic Affairs
  • Institute Physician
  • Stephen B. Kay Family Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gastrointestinal cancers

Contact Information

  • Office Phone Number617-632-3474
  • Fax617-632-2260

Bio

Dr. Mayer received his MD from Harvard Medical School in 1969, and postgraduate training in internal medicine at Mount Sinai Hospital, New York City. After fellowships in hematology and oncology at the National Cancer Institute and Dana-Farber Cancer Institute, he joined Dana-Farber in 1974.

In 1997, he was president of the American Society of Clinical Oncology. Dr. Mayer currently serves as Faculty Vice President for Academic Affairs at Dana-Farber Cancer Institute and Faculty Associate Dean for Admissions at Harvard Medical School.

Board Certification:

  • Hematology, 1976
  • Internal Medicine, 1973
  • Medical Oncology, 1975

Fellowship:

  • Dana-Farber Cancer Institute, Hematology & Medical Oncology
  • National Cancer Institute, Medical Oncology

Residency:

  • Mount Sinai Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • Distinguished Achievement Award, American Society of Clinical Oncology 2019
  • Giants of Cancer, Gastrointestinal Cancer 2015
  • Ellen and Stephen Fine Award for Outstanding Teaching in Cancer Medicine, Dana-Farber Cancer Institute 2010
  • Sword of Hope Award, American Cancer Society Massachusetts Division 1995
  • George W. Thorn Award for Outstanding Contribution to Clinical Education 1990

Research

Multidisciplinary Research in Gastrointestinal Cancer

Gastrointestinal cancer ranks second only to respiratory cancer in the number of new cases and annual deaths in the United States each year. The term gastrointestinal cancer refers to malignant conditions of the esophagus, stomach, liver, biliary system, pancreas, small bowel, large bowel (i.e., colon and rectum), and anus.The Center for Gastrointestinal Oncology, directed by Dr. Mayer, is a multidisciplinary program to study this group of diseases. Our efforts include the identification and counseling of families at high risk of developing such disorders, the study of medical interventions to prevent the diseases, screening techniques to detect them at a preclinical stage, and the development of innovative treatment plans for diagnosed patients. Such efforts involve the participation of medical, radiation, and surgical oncologists, pathologists, gastroenterologists, social workers, and genetic counselors.The Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B, chaired by Dr. Mayer, is a multi-institutional collaboration supported by the National Cancer Institute. This research organization designs clinical trials conducted at DFCI and elsewhere throughout the United States.We also work regularly with pharmaceutical and biotechnology companies to examine experimental forms of therapy. Clinical trials are available for patients with each of the malignant conditions that gastrointestinal cancer comprises.Our work has been instrumental in studies which have defined optimal post-surgical (i.e., adjuvant) treatment for colon and rectal cancer and newer approaches to localized and advanced pancreatic cancer. In addition, Dr. Mayer has brought such new compounds as cetuximab to Dana-Farber for clinical testing.

Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 12 15; 25(24):7497-7505.
View in: PubMed

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
View in: PubMed

Reasons of reduced physical activity in preconception and pregnancy. Minerva Med. 2019 Jul 09.
View in: PubMed

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 04; 111:82-93.
View in: PubMed

Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
View in: PubMed

Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2018 12; 82(6):961-969.
View in: PubMed

NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. J Natl Compr Canc Netw. 2018 08; 16(8):939-949.
View in: PubMed

Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017.
View in: PubMed

Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
View in: PubMed

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. J Natl Compr Canc Netw. 2017 12; 15(12):1465-1475.
View in: PubMed

Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
View in: PubMed

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
View in: PubMed

Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
View in: PubMed

Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
View in: PubMed

Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374.
View in: PubMed

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53.
View in: PubMed

CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42.
View in: PubMed

Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
View in: PubMed

Colorectal Cancer Screening, Version 1.2015. J Natl Compr Canc Netw. 2015 Aug; 13(8):959-68; quiz 968.
View in: PubMed

Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14; 372(20):1909-19.
View in: PubMed

Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation. Clin Cancer Res. 2015 Apr 01; 21(7):1583-90.
View in: PubMed

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
View in: PubMed

Proteasome dysfunction activates autophagy and the Keap1-Nrf2 pathway. J Biol Chem. 2014 Sep 05; 289(36):24944-55.
View in: PubMed

Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
View in: PubMed

Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30.
View in: PubMed

Colorectal cancer screening. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1538-75.
View in: PubMed

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
View in: PubMed

Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013 Nov 15; 87(4):638-45.
View in: PubMed

Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
View in: PubMed

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87.
View in: PubMed

Reply to A. Grothey et al and R.S. Midgley et al. J Clin Oncol. 2013 Apr 20; 31(12):1612-3.
View in: PubMed

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol. 2013 May; 71(5):1241-6.
View in: PubMed

Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012 Dec 10; 30(35):4344-51.
View in: PubMed

Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012 Nov 21; 104(22):1702-11.
View in: PubMed

Clinical practice guidelines for cancer care: utilization and expectations of the practicing oncologist. J Oncol Pract. 2012 Nov; 8(6):350-3, 2 p following 353.
View in: PubMed

Oxaliplatin as part of adjuvant therapy for colon cancer: more complicated than once thought. J Clin Oncol. 2012 Sep 20; 30(27):3325-7.
View in: PubMed

Perspective: a culture of respect, part 1: the nature and causes of disrespectful behavior by physicians. Acad Med. 2012 Jul; 87(7):845-52.
View in: PubMed

Perspective: a culture of respect, part 2: creating a culture of respect. Acad Med. 2012 Jul; 87(7):853-8.
View in: PubMed

Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU Int. 2013 Jan; 111(1):114-21.
View in: PubMed

Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months. Pancreatology. 2012 Jan-Feb; 12(1):35-8.
View in: PubMed

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
View in: PubMed

Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
View in: PubMed

Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol. 2011 Aug 10; 29(23):3146-52.
View in: PubMed

Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol. 2011 Aug 10; 29(23):3153-62.
View in: PubMed

Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011 May 20; 29(15_suppl):4003.
View in: PubMed

Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. J Clin Oncol. 2011 May 20; 29(15_suppl):4005.
View in: PubMed

Long-term update of U.S. GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol. 2011 Feb; 29(4_suppl):367.
View in: PubMed

A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer. 2011 Jun 15; 117(12):2620-8.
View in: PubMed

Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010 Sep 01; 116(17):4007-13.
View in: PubMed

Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010 Oct 01; 28(28):4354-63.
View in: PubMed

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
View in: PubMed

By the way, doctor. I read that President Obama had a virtual colonoscopy. Is this the colon cancer screening test that everybody should be getting instead of a regular colonoscopy? I thought it was kind of experimental. Harv Health Lett. 2010 Jun; 35(8):8.
View in: PubMed

A step forward in the treatment of advanced biliary tract cancer. N Engl J Med. 2010 Apr 08; 362(14):1335-7.
View in: PubMed

The American Society of Clinical Oncology Cancer Foundation Grants Program: a 25-year report and a look toward the future. J Clin Oncol. 2010 Mar 20; 28(9):1616-21.
View in: PubMed

NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw. 2010 Jan; 8(1):8-61.
View in: PubMed

KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
View in: PubMed

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12.
View in: PubMed

KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
View in: PubMed

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. J Clin Oncol. 2009 May 20; 27(15_suppl):4012.
View in: PubMed

By the way, doctor. We have screening tests for other cancers. How about pancreatic cancer? Harv Health Lett. 2009 May; 34(7):1.
View in: PubMed

Sexual functioning, catastrophizing, depression, and pain, as predictors of quality of life in women with interstitial cystitis/painful bladder syndrome. Urology. 2009 May; 73(5):987-92.
View in: PubMed

A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 2009 Apr 07; 6(4):e1000046.
View in: PubMed

p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803. Clin Cancer Res. 2009 Mar 15; 15(6):2116-22.
View in: PubMed

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009 Apr 10; 27(11):1814-21.
View in: PubMed

Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med. 2009 Feb 05; 360(6):623-5.
View in: PubMed

Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
View in: PubMed

US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21.
View in: PubMed

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
View in: PubMed

Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008 Sep 01; 26(25):4109-15.
View in: PubMed

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol. 2008 Oct 01; 26(28):4603-9.
View in: PubMed

Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Dis Colon Rectum. 2008 Aug; 51(8):1185-91; discussion 1191-4.
View in: PubMed

Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23.
View in: PubMed

The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. J Clin Oncol. 2008 May 20; 26(15_suppl):4039.
View in: PubMed

Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol. 2008 Jul 01; 26(19):3229-34.
View in: PubMed

Systemic treatment of colorectal cancer. Gastroenterology. 2008 May; 134(5):1296-310.
View in: PubMed

By the way, doctor. Cancer of the small intestine. Harv Health Lett. 2008 May; 33(7):7.
View in: PubMed

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21.
View in: PubMed

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008 Mar 01; 26(7):1086-92.
View in: PubMed

Followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus Calmette-Guerin or placebo. J Urol. 2008 Feb; 179(2):552-5.
View in: PubMed

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
View in: PubMed

A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
View in: PubMed

Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol. 2007 Sep 20; 25(27):4165-7.
View in: PubMed

Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15; 298(7):754-64.
View in: PubMed

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007 Aug 10; 25(23):3456-61.
View in: PubMed

Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? J Urol. 2007 Sep; 178(3 Pt 1):886-90.
View in: PubMed

Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9.
View in: PubMed

Sexual function is a determinant of poor quality of life for women with treatment refractory interstitial cystitis. J Urol. 2007 May; 177(5):1832-6.
View in: PubMed

Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007 May-Jun; 57(3):168-85.
View in: PubMed

Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
View in: PubMed

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62.
View in: PubMed

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006 Oct 20; 24(30):4914-21.
View in: PubMed

The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan; 132(1):127-38.
View in: PubMed

Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Sep; 35(3):713-27.
View in: PubMed

Development of glomerulations in younger women with interstitial cystitis. Urology. 2006 Aug; 68(2):253-6.
View in: PubMed

Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol. 2006 Aug 01; 24(22):3542-7.
View in: PubMed

Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41.
View in: PubMed

ECOG E3201: Intergroup randomized phase III study of postoperative irinotecan, 5- fluorouracil (FU), leucovorin (LV) (FOLFIRI) vs oxaliplatin, FU/LV (FOLFOX) vs FU/LV for patients (pts) with stage II/ III rectal cancer receiving either pre or postoperative radiation (RT)/ FU. J Clin Oncol. 2006 Jun 20; 24(18_suppl):3526.
View in: PubMed

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10003.
View in: PubMed

Intergroup RTOG 98-11: A phase III randomized study of 5-fluorouracil (5-FU), mitomycin, and radiotherapy versus 5-fluorouracil, cisplatin and radiotherapy in carcinoma of the anal canal. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4009.
View in: PubMed

Cancer and leukemia group B gastrointestinal cancer committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3589s-95s.
View in: PubMed

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3556s-63s.
View in: PubMed

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol. 2006 Jun 01; 24(16):2557-62.
View in: PubMed

Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):384-420.
View in: PubMed

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006 Jul 01; 108(1):63-73.
View in: PubMed

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20; 24(9):1395-403.
View in: PubMed

Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20; 24(6):878-83.
View in: PubMed

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
View in: PubMed

Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005 Dec 01; 23(34):8671-8.
View in: PubMed

Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005 Dec 01; 23(34):8706-12.
View in: PubMed

A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23.
View in: PubMed

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005 Aug 20; 23(24):5705-17.
View in: PubMed

Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3530.
View in: PubMed

The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3534.
View in: PubMed

Factors predicting willingness to participate in cancer genetic epidemiologic research. J Clin Oncol. 2005 Jun; 23(16_suppl):6007.
View in: PubMed

Consistent response to treatment with cetuximab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):3536.
View in: PubMed

Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. J Clin Oncol. 2005 Jun; 23(16_suppl):3595.
View in: PubMed

A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005 Apr; 173(4):1186-91.
View in: PubMed

Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005 Mar 20; 23(9):1819-25.
View in: PubMed

Systemic therapy for colorectal cancer. N Engl J Med. 2005 Feb 03; 352(5):476-87.
View in: PubMed

Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer. 2004 Dec 10; 112(5):754-9.
View in: PubMed

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan 20; 23(3):482-93.
View in: PubMed

APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. . 2004 Oct; 3(10):960-4.
View in: PubMed

Sentinel node staging of resectable colon cancer: results of a multicenter study. Ann Surg. 2004 Oct; 240(4):624-8; discussion 628-30.
View in: PubMed

Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004 Oct; 27(5):485-8.
View in: PubMed

Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3510.
View in: PubMed

A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3560.
View in: PubMed

Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3500.
View in: PubMed

Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic stem cell transplantation (ASCT) for acute myeloid leukemia (AML) patients <60 years with normal cytogenetics: A Cancer and Leukemia Group B (CALGB) Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):6542.
View in: PubMed

A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4011.
View in: PubMed

Two steps forward in the treatment of colorectal cancer. N Engl J Med. 2004 Jun 03; 350(23):2406-8.
View in: PubMed

Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res. 2004 May 01; 64(9):3014-21.
View in: PubMed

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96.
View in: PubMed

Gastrointestinal cancer in older patients. Semin Oncol. 2004 Apr; 31(2):206-19.
View in: PubMed

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
View in: PubMed

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004 Apr 01; 22(7):1201-8.
View in: PubMed

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004 Jun 01; 103(11):4036-42.
View in: PubMed

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004 Feb 15; 22(4):648-57.
View in: PubMed

Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. . 2004 Jan; 3(1):73-8.
View in: PubMed

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Ann Hematol. 2004; 83 Suppl 1:S84-5.
View in: PubMed

A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22(3):353-9.
View in: PubMed

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 01; 22(1):166-74.
View in: PubMed

Esophageal cancer. N Engl J Med. 2003 Dec 04; 349(23):2241-52.
View in: PubMed

Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
View in: PubMed

Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol. 2003 Oct 01; 21(19):3623-8.
View in: PubMed

Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003 Aug 01; 98(3):484-95.
View in: PubMed

Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003 Aug 01; 21(15):2912-9.
View in: PubMed

Follow-up strategies after curative resection of colorectal cancer. Semin Oncol. 2003 Jun; 30(3):349-60.
View in: PubMed

Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr; 10(3):213-8.
View in: PubMed

Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003 Apr 01; 63(7):1608-14.
View in: PubMed

Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 01; 21(3):433-40.
View in: PubMed

Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003; 34(2-3):107-16.
View in: PubMed

A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11.
View in: PubMed

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002 Nov; 21(5):1041-51.
View in: PubMed

Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):409-13.
View in: PubMed

Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):386-96.
View in: PubMed

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9.
View in: PubMed

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002 Aug 07; 94(15):1160-7.
View in: PubMed

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15; 100(13):4325-36.
View in: PubMed

A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 2002 Jun 15; 94(12):3186-91.
View in: PubMed

Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. J Clin Oncol. 2002 Apr 01; 20(7):1744-50.
View in: PubMed

Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med. 2002 Feb 19; 136(4):261-9.
View in: PubMed

Merkel cell carcinoma. J Clin Oncol. 2002 Jan 15; 20(2):588-98.
View in: PubMed

A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 2002 Jan 01; 94(1):97-103.
View in: PubMed

Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same. J Clin Oncol. 2001 Nov 01; 19(21):4093-6.
View in: PubMed

Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May 01; 19(9):2413-21.
View in: PubMed

CALGB 9380: a prospective trial of the feasibility of thoracoscopy/laparoscopy in staging esophageal cancer. Ann Thorac Surg. 2001 Apr; 71(4):1073-9.
View in: PubMed

Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
View in: PubMed

Oxaliplatin-induced Evan's syndrome. Br J Cancer. 2001 Feb 02; 84(3):441.
View in: PubMed

Efficacy of neo- and adjuvant treatment modalities in gastrointestinal cancer patients. Swiss Surg. 2001; 7(6):239-42.
View in: PubMed

Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol. 2001 Jan 01; 19(1):205-12.
View in: PubMed

Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol. 2001 Jan 01; 19(1):157-63.
View in: PubMed

Attitudes and practices of U.S. oncologists regarding euthanasia and physician-assisted suicide. Ann Intern Med. 2000 Oct 03; 133(7):527-32.
View in: PubMed

Moving beyond fluorouracil for colorectal cancer. N Engl J Med. 2000 Sep 28; 343(13):963-4.
View in: PubMed

Diagnostic dilemmas in oncology. Case 3. Metastatic ovarian cancer simulating colon cancer. J Clin Oncol. 2000 Sep; 18(17):3189-92.
View in: PubMed

Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000 Jul; 12(4):345-52.
View in: PubMed

Chemoprevention of colorectal cancer. N Engl J Med. 2000 Jun 29; 342(26):1960-8.
View in: PubMed

Carcinoma of the anal canal. N Engl J Med. 2000 Mar 16; 342(11):792-800.
View in: PubMed

A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer. 2000 Jan 01; 88(1):180-5.
View in: PubMed

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999 Dec; 17(12):3767-75.
View in: PubMed

Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999 Jul-Aug; 6(5):433-41.
View in: PubMed

Carcinoid tumors. N Engl J Med. 1999 Mar 18; 340(11):858-68.
View in: PubMed

Third International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Cologne, 23-26 September 1998. Ann Oncol. 1999 Mar; 10(3):281-7.
View in: PubMed

Multidisciplinary gastrointestinal cancer clinic: abdominal radiologist as active participant. Acad Radiol. 1998 Oct; 5(10):694-7.
View in: PubMed

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 Sep 15; 58(18):4173-9.
View in: PubMed

The state of the society: a year of continued growth. J Clin Oncol. 1998 Sep; 16(9):3192-8.
View in: PubMed

Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998 Mar; 9(3):297-306.
View in: PubMed

Cancer care during the last phase of life. J Clin Oncol. 1998; 5:1986-1996.

Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood. 1997 Dec 01; 90(11):4532-8.
View in: PubMed

Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer. 1997 Nov 15; 80(10):1936-44.
View in: PubMed

Winning the war on cancer. N Engl J Med. 1997 Sep 25; 337(13):935; author reply 937-8.
View in: PubMed

Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study. J Clin Oncol. 1997 May; 15(5):1786-95.
View in: PubMed

Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461. J Clin Oncol. 1997 Feb; 15(2):466-75.
View in: PubMed

Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997 Feb; 112(2):594-642.
View in: PubMed

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997 Jan; 15(1):246-50.
View in: PubMed

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol. 1996 Sep; 14(9):2486-94.
View in: PubMed

The status of the medical oncology workforce a report from the ad hoc committee of the American Society of Clinical Oncology. J Clin Oncol. 1996; 14:2612-2621.

Adjuvant chemotherapy for colon and rectal cancer. Semin Oncol. 1995 Oct; 22(5):472-87.
View in: PubMed

Summary of the Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies. Ann Oncol. 1995 Sep; 6(7):645-9.
View in: PubMed

Gastric carcinoma. N Engl J Med. 1995 Jul 06; 333(1):32-41.
View in: PubMed

Morphologic characteristics of erythroleukemia (acute myeloid leukemia; FAB-M6): a CALGB study. Am J Hematol. 1995 May; 49(1):29-38.
View in: PubMed

Clinical pharmacology of cytarabine in patietns with acute myeloid leukemia: a Cancer and Leukemia Group B study. Cancer Chemother and Pharmacol. 1995; 36:425-430.

Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study. Cancer Chemother and Pharmacol. 1995; 36:425-430.

A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: follow-up report. J Hepatic Biliary Pancreatic Surg. 1995; 2:122-125.

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 06; 331(14):896-903.
View in: PubMed

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994 Aug 25; 331(8):502-7.
View in: PubMed

The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am. 1994 Jun; 8(3):533-53.
View in: PubMed

Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994 Mar 15; 83(6):1603-11.
View in: PubMed

Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1993 Dec 15; 85(24):1994-2003.
View in: PubMed

Primary central nervous system lymphoma. Ann Intern Med. 1993 Dec 01; 119(11):1093-104.
View in: PubMed

Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst. 1993 Nov 17; 85(22):1839-44.
View in: PubMed

Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg. 1993 May; 128(5):559-64.
View in: PubMed

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes. Am J Clin Oncol. 1993 Apr; 16(2):159-63.
View in: PubMed

Overview: the changing nature of esophageal cancer. Chest. 1993 Apr; 103(4 Suppl):404S-405S.
View in: PubMed

Treatment of the newly diagnosed adult with de novo acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):47-64.
View in: PubMed

The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am. 1993 Feb; 7(1):65-79.
View in: PubMed

Adjuvant Chemotherapy for Colon and Rectal Cancer. Semin Radiat Oncol. 1993 Jan; 3(1):29-41.
View in: PubMed

Some considerations concerning the dose and schedule of 5FU and leucovorin: toxicities of two dose schedules from the intergroup colon adjuvant trial (INT-0089). Adv Exp Med Biol. 1993; 339:51-4; discussion 55-6.
View in: PubMed

Chemotherapy for metastatic colorectal cancer. Cancer. 1992 Sep 01; 70(5 Suppl):1414-24.
View in: PubMed

Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992 Jun; 10(6):948-53.
View in: PubMed

Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol. 1992 Apr; 10(4):536-40.
View in: PubMed

Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B. Leukemia. 1992; 6 Suppl 2:66-7.
View in: PubMed

Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol. 1992; 10:549-557.

Preservation of sphincter function in rectal carcinoma by a multimodality treatment approach. Surg Clin N Am. 1992; 1:137-145.

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991 Dec; 9(12):2128-33.
View in: PubMed

Systemic therapy for colorectal cancer: an overview. Semin Oncol. 1991 Oct; 18(5 Suppl 7):62-6.
View in: PubMed

A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991 Jul; 9(7):1105-12.
View in: PubMed

Training in medical oncology: regaining the luster. J Natl Cancer Inst. 1991 Jun 19; 83(12):806-7.
View in: PubMed

A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg. 1991 Jun; 126(6):696-701; discussion 701-2.
View in: PubMed

Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15; 77(10):2242-50.
View in: PubMed

Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia. 1991 May; 5(5):425-31.
View in: PubMed

Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6.
View in: PubMed

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia. 1991 Mar; 5(3):230-8.
View in: PubMed

A phase I study of intermittent continuous infusion high dose cytosine arabinoside for acute leukemia. Leukemia. 1990 Dec; 4(12):843-7.
View in: PubMed

The unique aspects of acute promyelocytic leukemia. J Clin Oncol. 1990 Nov; 8(11):1913-21.
View in: PubMed

Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Am J Hematol. 1990 Oct; 35(2):80-3.
View in: PubMed

Intensive chemotherapy versus allogeneic bone marrow transplantation in first-remission acute myeloid leukemia. Bone Marrow Transplant. 1990 Jul; 6 Suppl 1:48-51.
View in: PubMed

Acute leukemias in adults: an overview of recent strategies. J Cancer Res Clin Oncol. 1990; 116(1):94-6.
View in: PubMed

A prospective trial of rcombinant human interferon alpha 2b in previously untreated patients with hepatocellular carcinoma. Cancer. 1990; 66:135-139.

Pregnancy and leukemia. Semin Oncol. 1989 Oct; 16(5):388-96.
View in: PubMed

The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989 Oct; 7(10):1419-26.
View in: PubMed

Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst. 1989 Sep 20; 81(18):1359-64.
View in: PubMed

Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol. 1989 Apr; 30(4):221-7.
View in: PubMed

The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988 Dec; 148(12):2561-8.
View in: PubMed

Value of a routine follow-up endoscopy program for the detection of recurrent colorectal carcinoma. Am J Gastroenterol. 1988 Dec; 83(12):1355-60.
View in: PubMed

Allogeneic transplantation versus intensive chemotherapy in first-remission acute leukemia: is there a "best choice"? J Clin Oncol. 1988 Oct; 6(10):1532-6.
View in: PubMed

Prognostic factors for colon cancer. J Clin Oncol. 1988 Jun; 6(6):1066-7.
View in: PubMed

Prolonged high dose ARA-C infusions in acute leukemia. Leukemia. 1988 May; 2(5):304-6.
View in: PubMed

Primary gastrointestinal lymphoma. Semin Oncol. 1988 Apr; 15(2):154-69.
View in: PubMed

How is cancer treatment chosen? N Engl J Med. 1988 Mar 10; 318(10):636-8.
View in: PubMed

Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood. 1988 Mar; 71(3):690-6.
View in: PubMed

Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst. 1988; 80:1011-1015.

Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients. Am Heart J. 1987 Dec; 114(6):1432-5.
View in: PubMed

Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol. 1987 Dec; 14(4):384-96.
View in: PubMed

Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study. Cancer Treat Rep. 1987 Sep; 71(9):879-80.
View in: PubMed

Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Semin Oncol. 1987 Jun; 14(2 Suppl 1):25-31.
View in: PubMed

Comparison of unique leucovorin and 5-fluorouracil "escalating" and "maximum" dosage strategies. NCI Monogr. 1987; (5):179-84.
View in: PubMed

Phase II trials of the simple agents Baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Cancer Treat ep. 1987; 71:865-867.

Therapeutic strategies in acute myelocytic leukemia: a status report of the experience of CALGB. Cancer and Leukemia Group B. Haematol Blood Transfus. 1987; 30:31-4.
View in: PubMed

Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood. 1987 Jan; 69(1):187-91.
View in: PubMed

Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood. 1986 Dec; 68(6):1232-41.
View in: PubMed

Survival after postoperative combination treatment of rectal cancer. N Engl J Med. 1986 11 13; 315(20):1294-5.
View in: PubMed

Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986 Nov; 46(11):5953-8.
View in: PubMed

Adjuvant therapy in rectal cancer: a protocol proposal. Semin Oncol. 1985 Sep; 12(3 Suppl 4):116-20.
View in: PubMed

Amsacrine in refractory acute leukemia. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):787-9.
View in: PubMed

Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study. Semin Oncol. 1985 Jun; 12(2 Suppl 3):84-90.
View in: PubMed

Acute lymphoblastic leukemia in adults. Ann Intern Med. 1984 Oct; 101(4):552-4.
View in: PubMed

B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984 Aug; 74(2):332-40.
View in: PubMed

Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy. Am J Surg. 1984 Apr; 147(4):554-9.
View in: PubMed

Adjuvant therapy for colon cancer: Results of a prospectively randomized trial. N Engl J Med. 1984; 310:737-743.

Phase II study of methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in advanced colorectal cancer. J Clin Oncol. 1984; 2:770-773.

Immunological and cytogenetic studies in two cases of B-cell acute lymphoblastic leukemia (Burkitt's type). Cancer Genet Cytogenet. 1983 Oct; 10(2):167-75.
View in: PubMed

Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat Rep. 1983 Sep; 67(9):773-7.
View in: PubMed

Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes. Blood. 1983 Sep; 62(3):557-63.
View in: PubMed

Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983 Aug; 62(2):315-9.
View in: PubMed

Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol. 1983 May; 1(5):337-44.
View in: PubMed

Acute leukemia after radiotherapy in a patient with Turcot's syndrome. Impaired colony formation in skin fibroblast cultures after irradiation. Am J Med. 1983 Feb; 74(2):343-8.
View in: PubMed

The treatment of acute myelogenous leukemia in children and adults: VAPA update. Haematol Blood Transfus. 1983; 28:41-5.
View in: PubMed

Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum. 1982 Nov-Dec; 25(8):749-54.
View in: PubMed

The role of intensive postinduction chemotherapy in the management of patients with acute myelogenous leukemia. Cancer Treat Rep. 1982 Jul; 66(7):1455-62.
View in: PubMed

More than MOPP for advanced Hodgkin's disease? N Engl J Med. 1982 Apr 01; 306(13):800-2.
View in: PubMed

Heterogenous response to X-ray and UV light irradiation of cultured skin fibroblasts in two families with Gardner's syndrome. J Natl Cancer Inst. 1982; 68:697-701.

A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer. 1982; 49:1771-1777.

Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981 Aug; 71(2):246-53.
View in: PubMed

Phase I--II trial of methyl-GAG in the treatment of patients with metastatic renal adenocarcinoma. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):17-20.
View in: PubMed

VAPA10: a treatment program for acute myelocytic leukemia. Haematol Blood Transfus. 1981; 26:45-52.
View in: PubMed

The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers. Ann Surg. 1980 Dec; 192(6):747-51.
View in: PubMed

Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. Cancer Res. 1980 Oct; 40(10):3430-6.
View in: PubMed

Treatment of acute myelogenous leukemia in children and adults. N Engl J Med. 1980 Aug 28; 303(9):473-8.
View in: PubMed

Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg. 1980 Apr; 139(4):544-8.
View in: PubMed

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6.
View in: PubMed

Testicular self-examination. N Engl J Med. 1980 Jan 31; 302(5):297.
View in: PubMed

Phase I trial of bruceantin. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1929-32.
View in: PubMed

Microangiopathic hemolytic anemia and cancer: a review. Medicine (Baltimore). 1979 Sep; 58(5):377-84.
View in: PubMed

The rate of postoperative CEA rise in selecting treatment for recurrent colorectal cancer. Gastroenterology. 1979; 76:1223.

Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer. 1978 Sep; 42(3 Suppl):1428-33.
View in: PubMed

Transient carcinoembryonic antigen (CEA) elevations following resection of colorectal cancer: a limitation in the use of serial CEA levels as an indicator for second-look surgery. J Natl Cancer Inst. 1978 Aug; 61(2):315-8.
View in: PubMed

Circulating immune complexes in patients following clinically curative resection of colorectal cancer. Surgery. 1978 Jun; 83(6):648-54.
View in: PubMed

Acute renal failure associated with neoplastic disease and its treatment. Semin Oncol. 1978 Jun; 5(2):155-65.
View in: PubMed

Central nervous system involvement by ovarian carcinoma: a complication of prolonged survivial with metastatic disease. Cancer. 1978 Feb; 41(2):776-83.
View in: PubMed

A therapeutic trial of maytansine. Cancer Clin Trials. 1978; 1(2):113-7.
View in: PubMed

Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. Cancer. 1977 Dec; 40(6):2792-6.
View in: PubMed

Adriamycin plus alkylating agents in the treatment of metastatic breast cancer. Cancer. 1977 Dec; 40(6):2801-5.
View in: PubMed

DNA-metabolizing enzymes in normal human lymphoid cells. VI. Induction of DNA polymerases alpha, beta, and gamma following stimulation with phytohemagglutinin. Blood. 1975 Oct; 46(4):509-18.
View in: PubMed

Relationships between components in primate RNA tumor viruses and in the cytoplasm of human leukemic cells: implications to leukemogenesis. Cold Spring Harb Symp Quant Biol. 1975; 39 Pt 2:933-61.
View in: PubMed

Reverse transcriptase in normal rhesus monkey placenta. Science. 1974 Sep 06; 185(4154):864-7.
View in: PubMed

Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer. 1973 Oct; 32(4):771-88.
View in: PubMed

Dreaming and Korsakoff's psychosis. Arch Gen Psychiatry. 1968; 18:203-209.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1602
Boston, MA 02215
Get Directions

Ratings

Top